Rajah & Tann Asia Member Firms, Members of Lifesciences Asia-Pacific Network, Produce Guides to Support the Lifesciences Sector on Legal Issues
Two member firms of Rajah & Tann Asia, Rajah & Tann Singapore and Assegaf Hamzah & Partners, are members of the Lifesciences Asia-Pacific Network (“LAN“) which was established for the Lifesciences sector to support and guide clients on all their legal and regulatory needs in the Asia-Pacific region. LAN’s members include other leading and largest law firms in the region, such as Atsumi & Sakai in Japan, Chen & Lin in Taiwan, CMS in China and Hong Kong, Corrs Chambers Westgarth in Australia, Khaitan & Co in India, Tilleke & Gibbins in Thailand and Vietnam, and Yulchon LLC in Korea.
To help the Lifesciences sector navigate key legal and commercial issues while doing business in the Asia-Pacific region, LAN publishes the following three guides:
- Comparative Guide on Data Protection Across Asia-Pacific – The guide provides a comparative overview of the latest data protection developments across the Asia-Pacific region, particularly in the jurisdictions which have seen significant changes in this area in the recent months, such as China, India, Korea, Singapore, Taiwan, Thailand and Vietnam. The guide discusses, in Question-and-Answer format, how personal, health-related and other data that are collected and used in the lifesciences and healthcare sector are regulated in each of the covered jurisdictions.
- A Comparative Overview of Distribution and Marketing of Drugs Across Asia-Pacific – The guide looks into the distribution and marketing of drugs in Australia, China, India, Indonesia, Japan, Korea, Singapore, Taiwan, Thailand and Vietnam. It also highlights the key legal and commercial issues that companies must take into account when doing business relating to drug distribution and marketing in these jurisdictions, in order to maximise opportunity and minimise risk.
- A Comparative Overview of Intellectual Property and Lifesciences Regulation Across Asia-Pacific – The guide provides a comparative overview of the regulatory and intellectual property (IP) considerations in the following priority jurisdictions for the Lifesciences sector: Australia, China, India, Indonesia, Japan, Korea, Singapore, Taiwan, Thailand and Vietnam. It also covers areas such as advertising, packaging and labelling of medicinal products, clinical trials and restrictions on dealings with healthcare professionals.
Lim Wee Hann, Partner with Rajah & Tann Singapore who specialises in Lifesciences, and Eko Basyuni, Partner with Assegaf Hamzah & Partners, contributed to these Guides to share their insights on Singapore and Indonesian laws, respectively, on the issues expounded in the Guides.
